HCC1954 Xenograft Model Service for Breast Cancer

The HCC1954 xenograft model serves as a powerful and translationally valuable in vivo platform specifically designated for evaluating therapeutic candidates targeting HER2-positive breast cancers with inherent PIK3CA mutations. Alfa Cytology delivers a comprehensive, end-to-end HCC1954 xenograft model service, combining optimized cell preparation methodologies with precise procedural and inoculation protocols to accelerate your preclinical oncology drug discovery timeline.

Overview of HCC1954 Xenograft Model for Breast Cancer

The HCC1954 cell line is a highly characterized human mammary carcinoma model known for its dual genomic hallmarks: significant amplification/overexpression of the human epidermal growth factor receptor 2 (HER2/ERBB2) oncogene and a concomitant activating mutation in the PIK3CA gene (specifically H1047R in exon 20). Derived from a primary ductal carcinoma, this model molecularly represents an aggressive subset of HER2-positive breast cancers. Because the PIK3CA mutation hyperactivates the downstream PI3K/Akt/mTOR signaling pathway, HCC1954 cells exhibit intrinsic resistance to first-generation HER2-targeted therapies such as trastuzumab. Consequently, this model is an indispensable preclinical tool for exploring resistance mechanisms and validating next-generation therapies, including novel antibody-drug conjugates (ADCs), dual HER2/EGFR inhibitors, and combination regimens targeting both HER2 and the PI3K pathway.

When established in vivo as a xenograft in immunocompromised mice, HCC1954 cells rapidly form solid tumors that preserve the histological architecture, receptor status, and specific genetic mutations of the clinical disease. The model is characterized by robust and highly predictable growth kinetics, providing a reliable and uniform testing window for efficacy screening and pharmacodynamic profiling.

Fig 1. HzMUC1 antibody binds to MUC1 on the cell surface of HER2-positive breast cancer cells. (Wu G, et al., 2021)

Cell Line Information: HCC1954

The HCC1954 cell line maintains a stable epithelial morphology in vitro and reliably preserves its signature HER2 amplification and PIK3CA mutation status upon in vivo transplantation.

Alfa Cytology is dedicated to upholding the highest benchmarks of scientific precision across all our tumor modeling operations. Our specialized oncology team utilizes fully authenticated cell lines and carefully monitored protocols to safeguard the genetic and phenotypic stability of the HCC1954 model throughout the lifecycle of your study.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the HCC1954 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for HER2 expression and PK/PD profiling. Leveraging our expertise in HER2-positive/PIK3CA-mutant breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of HCC1954 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the HCC1954 xenograft model:

• Cell Culture & Quality Control: HCC1954 cells are cultivated in optimized growth media. Comprehensive quality controls, including STR profiling and contamination screening, are performed to guarantee high cell viability and phenotypic identity before inoculation.
• Host Adaptation: Standardized immunocompromised mice are selected based on the study design and allowed to acclimate to our controlled facility parameters to achieve baseline physiological stability.
• Precision Inoculation: A highly viable, calibrated suspension of HCC1954 cells is prepared and blended with a biological matrix carrier to optimize cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. HCC1954 Xenograft Model Construction Workflow

Case Study - HCC1954 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the HCC1954 xenograft model was successfully utilized to evaluate the efficacy of a next-generation PARP inhibitor candidate. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms under optimized modeling conditions, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group compared to the vehicle control.

Our Advantages

Choosing the right partner for your HER2-positive, PIK3CA-mutated breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Advanced Modeling Expertise: Broad proficiency in establishing and characterizing a diverse portfolio of human tumor models.
• Stringent Quality Control: All cell lines undergo rigorous authentication, including STR profiling, to secure baseline stability.
• Technical Reproducibility: Optimized inoculation methodologies designed to achieve uniform tumor growth kinetics.
• Comprehensive Readouts: Fully equipped to deliver multi-parametric endpoints, including high-precision tumor tracking and PK/PD tissue processing.
• Scientific Integrity: All studies are executed by a specialized team providing publication-ready data and transparent reporting.

Contact Us

Are you looking to advance your therapeutic pipeline against HER2-positive, PIK3CA-mutated breast cancer using the robust HCC1954 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.